TNF and infection: While waiting for bifunctional antibodies, the dual-target with anti-TNFα (certolizumab), followed by targeting IL-17A-F (ixekizumab), led to faster and stronger disease control in anti-TNFα incomplete responders, at the expense of more, not severe, infections (114).